Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab ...

The neu gene encodes a 185-kDa transmembrane glycoprotein, referred to as p185neu, HER2, or erbB-2, possessing intrinsic protein tyrosine kinase activity. The receptor consists of an extracellular ...

Their study, published in the online journal, Breast Cancer Research, on Nov. 29, 2004, showed that the vaccine protected 86 percent of experimental mice against HER2/neu-associated breast cancer ...

Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

The FISH (fluorescence in situ hybridization) test checks the DNA of your cancer cells for extra copies of the HER2/neu gene. This gene makes proteins called HER2 (human epidermal growth factor ...

It works against a protein called HER2 (also sometimes referred to as HER2/neu), which is short for human epidermal growth factor receptor 2. Herceptin can treat early lymph node-positive and more ...

They also assess this HER2/neu protein to determine: is this one of the cases that is overexpressed and has excess protein? Or is this indeed a case where there is the standard amount of HER2/neu ...

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.

the VENTANA HER2/neu (4B5) IUO (investigational use only) Assay system, according to an algorithm adapted from the 2018 American Society of Clinical Oncology–College of American Pathologists ...

The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay. Additionally, the American Society for Clinical Pathology has guidelines for testing for HER2. Support for the ...

But the biotech pushes on, licensing Mayo Clinic's HER2/neu vaccine technology to develop vaccines for any cancer where the HER2/neu gene is overexpressed. Mayo Clinic initially licensed the ...